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Recent warnings by regulatory bodies and a product recall by
the FDA have generated much interest in the area of dose dump-
ing from controlled-release opioid analgesic formulations when
coingested with alcohol. It was the aim of this study to address this
issue and in doing so, gain understanding on how alcohol-induced
effects may be avoided. In this study, tramadol release from
Ultram® ER tablets and T-long® capsules was significantly
increased in the presence of ethanol. Conversely, a decrease in the
rate of tramadol release was seen from TriduralTM extended-
release tablets in the presence of alcohol.
Keywords tramadol; controlled release; alcohol; in vitro
INTRODUCTION
Controlled-release formulations offering once a day delivery,
by definition, contain significant amounts of drug which, if
ingested as a single bolus dose, could cause severe adverse
events. Recently, a number of regulatory bodies around the
world, including the US FDA and Health Canada, have issued
warnings regarding the safety of controlled-release opioid–
analgesic formulations (FDA, 2005a) and, in some cases, prod-
ucts have been withdrawn from the market as a result. These
agencies have been specifically concerned with the potential
for alcohol interactions with controlled-release technologies of
these formulations to result in uncontrolled and early drug
release.
Recent interest in the effects of alcohol on the release of
drugs from controlled-release formulations arose following the
FDA recall of Palladone™ XL (FDA, 2005b). Palladone™ XL
was a marketed controlled-release opioid for the treatment of
moderate-to-severe chronic pain. It contained the long-acting
drug hydromorphone hydrochloride, which in overdose can
cause respiratory depression and coma (Spiller & Krenzelok,
1997). In the light of this recall, attention has focused on the
effects of coingestion of alcohol on the release profiles of other
drugs, and a recent study has examined the release of aspirin in
hydroethanolic media from hypromellose matrices (Roberts
et al., 2007).
Tramadol hydrochloride (HCl) is a synthetic centrally act-
ing aminocyclohexal analgesic that acts as an opioid agonist
with selectivity for the μ-receptor (Obaidat & Obaidat, 2001;
Scott & Perry, 2000). Although the analgesic effects of trama-
dol are comparable with those of strong opioids such as
morphine (Beaulieu et al., 2007), the use of tramadol may be
preferable to other opioids because at therapeutic doses it lacks
the typical opioid side effects producing no clinically relevant
cardiovascular effects (Chrubasik et al., 1992; Scott & Perry,
2000) and only mild respiratory depression (Houmes, Voets,
Verkaaik, Erdmann, & Lachmann, 1992). Typical adverse
events include nausea, vomiting, dizziness, and vertigo, which
although not life-threatening may become severe and poten-
tially dangerous to some patients if uncontrolled release
occurred; for example, dizziness and vertigo are of particular
importance to elderly patients for whom falls could have seri-
ous consequences. The half-life of the drug is approximately
5.5 h and thus a sustained release formulation is desirable so as
to reduce the frequency of administration and ensure better
patient compliance: its high solubility in water (Tiwari,
Murthy, Pai, Mehta, & Chowdary, 2003) dictates careful selec-
tion of the release-retarding excipients.
To date, there have been no reported studies of the effects of
alcohol on the release rate, in vitro, of drug from different
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controlled-release formulations. Accordingly, the aim of this
study was to evaluate the effect of increasing doses of alcohol
on the controlled-release performance of three once-daily
formulations of tramadol and to gain insight into how such
interactions might be avoided. Such formulations may be
administered to a dose of up to 400 mg/day. The three formula-
tions evaluated were Ultram® ER tablets (developed by Biovail
Inc.), Tridural™ extended-release tablets (developed by
Labopharm Inc.), and T-long® capsules (initially developed by
SMB), which are based on differing release technologies.
Ultram® ER tablets are marketed in the United States by
Ortho-McNeil, Inc., and are formulated with SmartCoat® tech-
nology. These tablets consist of a solid tablet core that contains
the drug, surrounded with a release-controlling coating com-
posed of water-insoluble and water-soluble polymers and plas-
ticizer (Ultram® ER package insert). These polymers of
opposite wettability act in concert to control the drug release
from the tablet.
Tridural™ extended-release tablets manufactured by
Labopharm Inc. (distributed in Canada, and marketed in
Europe as Contramal® UNO, Dolpar®, Monoalgic® L.P.,
Monotramal® L.P., Noax™ UNO, Tradorec XL, Tramadolor®,
and Unitrama) comprise a core tablet consisting principally of
Contramid®-modified pregelatinized starch and tramadol. In
contact with water, the Contramid® technology forms a semi-
permeable release-controlling membrane that provides zero-
order drug release for sustained analgesia. The core tablet is
surrounded by a polyvinylpyrrolidone–polyvinyl acetate
copolymer/xanthan gum/tramadol coating matrix that effects
rapid, yet controlled release to allow early analgesic onset
(Rahmouni et al., 2005).
T-long® capsules (manufactured by SMB and marketed in
Germany by AWD.pharma GmbH & Co. KG, also marketed
in Europe under brand names Dolodol™, Monocrixo® LP,
Tralodie®, and Tramium™) are hard gelatin capsules contain-
ing controlled-release film-coated tramadol pellets. Here the
drug is dispersed into pellets comprising microcrystalline cel-
lulose, saccarose stearate, hypromellose, and other excipients.
The pellets are coated using Eudragit® NE30D, a release-con-
trolling polymer, and filled into a capsule.
It is often difficult to obtain detailed and precise perfor-
mance information for the proprietary controlled-release mech-
anisms used in sustained-release products; in consequence, it is
equally difficult to provide information to the physician and
the patient regarding potentially dangerous performance defi-
cits when such products are taken with common beverages
including alcohol. By determining the effect of commonly
imbibed alcohol concentrations on release performance of each
formulation under test in vitro and ascribing this to a particular
aspect of the composition, we aimed not only to assist the user
and prescriber, but also the formulator of controlled-release
products. Alcohol concentrations of up to 40% (wt/wt) were
used, equivalent to those present in undiluted spirits such as
whisky and vodka.
MATERIALS AND METHODS
Materials
High-performance liquid chromatography (HPLC) grade
acetonitrile and absolute ethanol were purchased from Fisher
Scientific (UK). Ammonium hydroxide (28–30%, wt/wt),
perchloric acid (70%), potassium phosphate monobasic, and
sodium hydroxide pellets were purchased from Acros Organics
Ltd. (UK). Tramadol HCl (99.6%) was obtained from Chem-
agis Ltd. (Israel), 200 mg Tridural™ tramadol HCl extended-
release tablets were obtained from Labopharm Inc. (Canada),
200 mg Ultram® ER tablets from PriCara™ (Canada, a unit of
Ortho-McNeil, Inc., NJ, USA), and T-long® 200-mg capsules
were obtained from AWD Pharma (Germany). Water was
purified using a Milli Q system.
Methods
Buffer Preparation
Phosphate buffer, pH 6.8, was prepared using potassium
phosphate monobasic (68 g) and sodium hydroxide (9 g).
These were weighed into a 10-L volumetric flask to which
5 L of deionized water was added. When fully dissolved, the
volume was made up to 10 L using deionized water. The pH
was adjusted to 6.8 ± 0.05 with sodium hydroxide solution
(2 M).
Phosphate buffer, pH 6.8, containing 20% (vol/vol) ethanol
was prepared by adding 1 L of absolute ethanol to 4 L of phos-
phate buffer, pH 6.8, in a 5-L Erlenmeyer flask. Phosphate
buffer, pH 6.8, containing 40% (vol/vol) ethanol was prepared
by adding 2 L of absolute ethanol to 3 L of phosphate buffer,
pH 6.8, in a 5-L Erlenmeyer flask.
Mobile Phase Preparation
In a 1-L volumetric flask, 5 mL perchloric acid was added
to approximately 950 mL of water. The contents were mixed
and 3.4 mL ammonium hydroxide solution was added. The
contents were mixed again and made up to volume using
water. The pH of the final solution was confirmed to be
between 2 and 3. Acetonitrile (230 mL) was added to 770 mL
perchloric acid–ammonium hydroxide solution, mixed, filtered
through a 0.2-μm nylon membrane filter, and degassed.
HPLC Assay
Samples were assayed by HPLC using a Waters 2695 Alli-
ance Separation Module with a Waters 2487 dual-wavelength
absorbance detector with subsequent analysis using Empower
Pro Software version 5.00. A Lichrospher 5 μm RP Select B 60
Å column (4 mm i.d. × 125 mm) fitted with a RP select B
Guard Column were used. The mobile phase consisted 77%
aqueous solution (as prepared above) and 23% acetonitrile.
Detection was by UV at 273 nm with an injection volume of 20
μL and a flow rate of 1 mL/min. The retention time of tramadol
HCl was 8.8 min.
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Standard Preparation
Tramadol HCl (55.5 mg) was accurately weighed into a
100-mL volumetric flask and dissolved in buffer, pH 6.8, to
create a stock solution of 0.555 mg/mL. This stock solution
was sequentially diluted to obtain a calibration curve between
0.0111 and 0.2775 mg/mL. All dilutions were carried out in
grade A volumetric flasks using buffer, pH 6.8. When the dis-
solution studies were carried out in alcoholic buffer, pH 6.8
(20 or 40% ethanol), the stock solution and the subsequent
standards were prepared in the same dissolution medium. The
limits of detection and quantification were dependent on the
dissolution media used and are shown in Table 1 The precision
of the assay was determined by conducting repeat injections of
selected standards and the relative standard deviation of the
repeatability between samples found to be 0.3%.
Dissolution Testing of Formulations
Drug release from the formulations was monitored according
to USP (United States Pharmacopeia) general chapters section
711 using a Type 1 USP basket apparatus. A volume of 900 mL of
media was used in each dissolution vessel with a basket rotation
speed of 100 rpm confirmed by use of a tachometer. The dissolu-
tion media consisted of either phosphate buffer, pH 6.8, 20%
ethanol in phosphate buffer, pH 6.8, or 40% ethanol in phosphate
buffer, pH 6.8. Dissolution testing of the three formulations was
carried out on 6 tablets/capsules over a 24-h period with sampling
time points at 0.5, 1, 2, 4, 7, 9, 12, 16, and 24 h. Samples (3 mL) of
media were withdrawn from the dissolution vessels at each time
point using a 5-mL syringe connected to compatible, inert tubing.
The tubing was then removed and a PTFE filter (pore size
0.45 μm) was connected to the syringe. The first 2 mL of medium
was discarded while filtering and the remaining 1 mL was filtered
into a HPLC vial. The samples were then analyzed by HPLC
using the analytical method described above.
Statistical Analysis
Statistical analysis was performed on the dissolution data in
the form of a two-way ANOVA (analysis of variance) using
Mini-tab software.
Results
Ultram® ER tablets contain povidone (used as binder) that is
soluble in ethanol and ethylcellulose (used as a film coating),
the solubility of which depends on the degree of substitution of
the epoxy group. However, the grade used in this formulation
(Surelease) is soluble in ethanol. Ultram® ER tablets also con-
tain polyvinyl alcohol (used as pore former) that is slightly sol-
uble in ethanol (95%) and the rest of the excipients (lubricant,
glidant, and plasticizer) are used in this formulation at very
small amounts. The main excipient in the T-long® capsules is
Eudragit NE30D (used as a film coating) that is soluble in alco-
hol. Tridural™ tablets contain Kollidon SR (physical mixture
of polyvinylacetate [80%] and povidone [19%]) of which the
polyvinylacetate is insoluble in ethanol but povidone is soluble
in ethanol. Tridural™ tablets also contain xanthan gum that is
practically insoluble in ethanol, and Contramid( that is a cross-
linked starch and is insoluble in alcohol.
The release profiles of tramadol HCl from the three formula-
tions in each of the tested media are shown in Figure 1. In the
absence of alcohol, tramadol release from Tridural™ tablets
was approximately 93% after 24 h; the release of tramadol from
Ultram® ER tablets was approximately 100% and from T-long®
capsules approximately 98% in the same period. These data
indicate that under the dissolution conditions used in this study
full release of tramadol was observed after 24 h in all cases.
However, there was a marked difference in the release profiles of
the dosage forms. Tramadol release from the Tridural™
extended-release tablets was zero order across the 4- to 16-h
time period. This was not the case with the other two dosage
forms where sigmoidal release profiles were generated, that is,
they do not follow any classic kinetics rate laws (e.g., zero-,
first-, second-order kinetics, or Higuchi). However, the release
appears to be fastest from the T-long® capsules.
Formulations also differed considerably in response to
increasing ethanol concentration. Thus, after 4 h, the percent-
age of tramadol released from the Tridural™ tablets in the
absence of ethanol was 38.37%. This decreased to 27.80% in
the presence of 20% alcohol (p ≤ .05) but addition of further
alcohol (40%) caused no further decrease (Table 2) This corre-
sponds to a release rate reduction of 25% over the first 4 h of
dissolution.
After 4 h, the percentage of tramadol released from the
Ultram® ER tablets was 19% in pH 6.8 buffer, but this
increased to 27% (p ≤ .05) and 62% (p ≤ .05) in 20% ethanol
buffer and 40% ethanol buffer, respectively (Table 2) An even
larger increase in the percentage release of tramadol from
T-long® capsules was found to occur after 4 h. The percentage
release increased from 47% in pH 6.8 buffer to 81% in 20%
ethanol buffer and 100% in 40% ethanol buffer (Table 1).
DISCUSSION
Controlled-release formulations by definition, contain large
amounts of drug and thus the release mechanism must be suffi-
ciently robust to prevent any possibility of uncontrolled release
leading to “dose dumping.” This is particularly important with
opioid drugs such as tramadol where adverse reactions can be
TABLE 1 
Limit of Detection and Limit of Quantification of 
Tramadol from Various Dissolution Media Using Validated 
HPLC Method
Buffer, 
pH 6.8
20% Ethanol
Buffer, pH 6.8
40% Ethanol
Buffer, pH 6.8
LOD (μg/mL) 1.6 1.0 1.3
LOQ (μg/mL) 4.8 2.5 3.9
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severe. The ability of controlled-release formulations to retain
their respective intended delivery profiles in the presence of
alcohol is of particular importance, given that some patients
are likely to coingest alcohol with these analgesics either
accidentally or deliberately. The release of tramadol from
Ultram® ER tablets and T-long® capsules in 20% ethanol
buffer was increased by almost 40 and 75%, respectively, after
4-h dissolution (Table 2) Conversely, the release of tramadol
from Tridural™ extended-release tablets was significantly
decreased (p ≤ .05) by the presence of alcohol in the dissolu-
tion media. These effects may be attributed to differences in
the controlled-release technologies employed, specifically the
solubilities of the inactive ingredients in alcohol.
The Tridural™ formulation comprises core and coat matri-
ces combined to generate a compression coated tablet
(Rahmouni et al., 2006). The core blend is predominantly a
mixture of Contramid®-modified pregelatinized starch and tra-
madol, designed to provide a sustained release of the active
ingredient and, thereby, 24-h efficacy. Contramid®-modified
starch is derived from high-amylose starch (containing
between 65 and 75% amylose) (Rahmouni et al., 2006) that is
cross-linked, modified, and heat-treated to form a matrix that,
on contact with water, swells to form a self-limiting controlled-
release material. Within 15 min of exposure to water, a highly
organized, uniform, and continuous semipermeable layer
forms around the tablet, which limits the rate of water influx
into the tablet and thus the hydration of the interior (Rahmouni
et al., 2005) thereby providing the required zero-order release.
Pregelatinized starches (such as Contramid® starch) are known
not to swell in alcohol; thus, in the presence of increasing alco-
hol concentrations, the formation of the release-controlling
membrane would be inhibited slowing drug release (Rahmouni
et al., 2006). The coat matrix containing xanthan gum, another
complex carbohydrate would be expected to be similarly
affected.
The barrier function of the SmartCoat® controlled-release
technology employed to formulate Ultram® ER tablets when
exposed to ethanol seems to be compromised resulting, as is
seen from the data presented here, in an increase in the release
rate under these conditions.
T-long® tablets are hard gelatin capsules containing con-
trolled-release film-coated tramadol pellets. Here the drug is
dispersed with other excipients into pellets that are coated
using Eudragit® NE30D, a release-controlling polymer, and
filled into a capsule. As with the Ultram® ER formulation,
Eudragit® NE30D is soluble in alcohol (Rowe, Shesky, &
Owen, 2006) and, under these conditions, its release-controlling
properties would also be compromised.
Given the predictive and directional nature of in vitro disso-
lution testing, these results suggest strongly that alcohol-soluble
excipients should not be included in the release-controlling
mechanism of drugs, where dose dumping can lead to danger-
ous adverse events; opioids such as tramadol, oxycodone, and
hydromorphone would fit into this class. These data also
suggest that coadministration of alcohol with Tridural™
extended-release tablets will result in a decreased liberation
rate of tramadol from the tablet. Should a patient, despite pack-
age insert warnings imbibe alcohol with the opioid, then such
reduced rates of drug release would be desirable. Therefore it
FIGURE 1. The effect of ethanol concentration in the dissolution media on
the percentage tramadol hydrochloride released from (A) Tridural™ tablets,
(B) Ultram® ER tablets, and (C) T-long® capsules.
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may be advisable that manufacturers include warnings, for
both the prescriber and patient, in package inserts stating that
the performance of controlled-release formulations may be
altered in the presence of alcohol at concentrations achieved in
the stomach after consumption of undiluted spirits such as
whisky and vodka.
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